The FDA has given the green light to Sanofi's drug Dupixent to be used as treatment in pediatric patients with chronic eosinophilic esophagitis, the pharmaceutical company announced Jan. 25.

Baptist Health's central pharmacy center is months away from filling up to 14,000 prescriptions a day, and the facility will be the nation's most automated central pharmacy. 

Walgreens has reached a $275,000 settlement with the state of Vermont over allegations that medication and vaccination errors and other alleged violations created unsafe conditions for patients and staff at the chain's pharmacies across the state. 

 Haleon, the maker of Robitussin, has issued a voluntary recall of eight lots of three varieties of its cough medicines due to microbial contamination. 

A regional poison control center suspects three cases of hypoglycemia in 2023 were linked to counterfeit versions of Ozempic, according to a Jan. 24 Reuters exclusive report.

A federal appeals court in New York has upheld an order that bars "pharma bro" Martin Shkreli from working in the pharmaceutical industry, according to court documents.

CVS Caremark will no longer handle pharmacy costs for Tyson Foods' 140,000 employees after the company cut its contract, CNBC reported Jan. 24. A few months ago, Blue Shield California curbed its yearslong partnership with the pharmacy benefit manager.

After discontinuing the use of semaglutide and liraglutide weight-loss medications, a majority of patients were able to maintain the same weight they were at when halting the use — or even continued to lose additional weight after one year, a new study revealed. 

The viral popularity of Ozempic, Wegovy, and other diabetes and weight loss drugs is affecting hospital operations in a roundabout way. 

The FDA is now calling for warning labels on all commercial CAR-T therapy products amid its investigation into 22 reports about a possible being linked to lymphoma. 

The FDA has published corrections and additions to a company's voluntary recall of eye drops after a wave of several others throughout 2023. 

A handful of pharmacists in Washington state are training to prescribe the abortion medication mifepristone, NPR reported Jan. 22. 

Over the last five years, Hagerstown, Md.-based Meritus Health cut the number of opiates prescribed by more than 55% in its effort to quell the national opioid epidemic. 

The End Drug Shortages Alliance appointed Terri Lyle Wilson as its new chair and appointed two board members Jan. 23. 

North Carolina's state health plan dropped new coverage for weight loss drugs Jan. 1, a decision that is expected to cost the state $54 million in lost drug rebates, WRAL News reported Jan. 12.

Some Blue Cross Blue Shield companies now cover two newly approved sickle cell gene therapies, which cost about $2 million and $3 million per dose. 

During a visit last summer, FDA inspectors flagged eight deficiencies at an Eli Lilly manufacturing plant in Branchburg, N.J., according to an inspection report Reuters obtained through a Freedom of Information Act Request. 

Despite their rise to popularity as solutions for weight loss, drugs like Ozempic and Wegovy can also lead to muscle loss, and now pharmaceutical companies are looking at ways to curb the unwanted side effect, according to The Wall Street Journal.

Physicians, drugmakers, obesity organizations and the FDA are fretting about compounded versions of popular weight loss and diabetes drugs, including Wegovy, Ozempic and Zepbound. 

Washington, D.C.-based Children's National Hospital administered Zynteglo, a $2.8 million gene therapy, to its first pediatric patient with the help of Clearway Health.